Phase II study of 131 I-metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP.
François SevrinHélène Kolesnikov-GauthierOlivier CougnencEmilie BogartGudrun SchleiermacherFrederic CourbonMarion GambartAnne-Laure GiraudetNadège CorradiniJean-Noël BadelErwann RaultAurore OudouxMarie Cécile Le DeleyDominique Valteau-CouanetAnne-Sophie DefachellesPublished in: Pediatric blood & cancer (2023)
MIITOP showed acceptable tolerability in this heavily pretreated population and encouraging survival rates in VHR-NBL when followed by busulfan-melphalan.
Keyphrases
- phase ii study
- open label
- acute myeloid leukemia
- acute lymphoblastic leukemia
- locally advanced
- placebo controlled
- diffuse large b cell lymphoma
- multiple myeloma
- randomized controlled trial
- clinical trial
- allogeneic hematopoietic stem cell transplantation
- squamous cell carcinoma
- free survival
- double blind
- study protocol